1 week Ago By Defense World Staff
West Pharmaceutical Services, Inc. ( NYSE:WST – Get Free Report )’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $312.
04 and traded as high as $331.66. West Pharmaceutical Services shares last traded at $327.
56, with a volume of 301,188 shares traded. Wall Street Analysts Forecast Growth Several research firms recently issued reports on WST. Bank of America boosted their price objective on West Pharmaceutical Services from $350.
00 to $355.00 and gave the company a “buy” rating in a report on Friday, December 13th. UBS Group upgraded shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $350.
00 to $390.00 in a research note on Thursday, December 12th. Finally, Wolfe Research started coverage on shares of West Pharmaceutical Services in a research report on Friday, December 13th.
They set a “peer perform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $437.
75. Read Our Latest Stock Analysis on West Pharmaceutical Services West Pharmaceutical Services Trading Down 0.4 % West Pharmaceutical Services ( NYSE:WST – Get Free Report ) last posted its earnings results on Thursday, October 24th.
The medical instruments supplier reported $1.85 EPS for the quarter, beating the consensus estimate of $1.50 by $0.
35. The firm had revenue of $746.90 million for the quarter, compared to analyst estimates of $709.
62 million. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.
37%. West Pharmaceutical Services’s revenue for the quarter was down .1% compared to the same quarter last year.
During the same quarter in the prior year, the company posted $2.16 earnings per share. On average, research analysts predict that West Pharmaceutical Services, Inc.
will post 6.64 EPS for the current fiscal year. West Pharmaceutical Services Increases Dividend The business also recently declared a quarterly dividend, which was paid on Wednesday, November 20th.
Shareholders of record on Wednesday, November 13th were paid a $0.21 dividend. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.
20. This represents a $0.84 annualized dividend and a yield of 0.
26%. The ex-dividend date was Wednesday, November 13th. West Pharmaceutical Services’s dividend payout ratio is currently 12.
46%. Insider Transactions at West Pharmaceutical Services In other West Pharmaceutical Services news, VP Charles Witherspoon sold 703 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $310.
40, for a total transaction of $218,211.20. Following the transaction, the vice president now owns 1,253 shares of the company’s stock, valued at $388,931.
20. The trade was a 35.94 % decrease in their ownership of the stock.
The transaction was disclosed in a filing with the SEC, which is available at this hyperlink . Insiders own 0.53% of the company’s stock.
Hedge Funds Weigh In On West Pharmaceutical Services A number of institutional investors have recently modified their holdings of WST. Ballentine Partners LLC increased its stake in West Pharmaceutical Services by 4.7% in the second quarter.
Ballentine Partners LLC now owns 742 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 33 shares during the period. Covestor Ltd increased its position in West Pharmaceutical Services by 14.3% in the 3rd quarter.
Covestor Ltd now owns 320 shares of the medical instruments supplier’s stock valued at $96,000 after acquiring an additional 40 shares during the period. UMB Bank n.a.
raised its stake in West Pharmaceutical Services by 1.2% during the 3rd quarter. UMB Bank n.
a. now owns 3,941 shares of the medical instruments supplier’s stock valued at $1,183,000 after acquiring an additional 47 shares during the last quarter. Kensington Investment Counsel LLC lifted its position in West Pharmaceutical Services by 2.
8% during the 3rd quarter. Kensington Investment Counsel LLC now owns 1,752 shares of the medical instruments supplier’s stock worth $526,000 after acquiring an additional 47 shares during the period. Finally, Empowered Funds LLC grew its stake in shares of West Pharmaceutical Services by 3.
9% in the 3rd quarter. Empowered Funds LLC now owns 1,377 shares of the medical instruments supplier’s stock valued at $413,000 after purchasing an additional 52 shares during the last quarter. 93.
90% of the stock is owned by institutional investors and hedge funds. About West Pharmaceutical Services ( Get Free Report ) West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Read More Five stocks we like better than West Pharmaceutical Services What Are Dividend Contenders? Investing in Dividend Contenders Work and Play: Investing in the Rise of Bleisure Travel Using the MarketBeat Stock Split Calculator Top Dividend Stocks to Buy Now as Bond Yields Could Lower What is Insider Trading? What You Can Learn from Insider Trading SAP: AI Tailwinds Accelerating Enterprise Cloud Business Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter ..
